Purpose: LATISSE is marketed for the treatment of hypotrichosis (loss of eyelashes), using a prostamide analogue and preserved with benzalkonium chloride, which is an effective preservative; however, it also causes irritation to the ocular surface. LATISSE is applied to the lid margin; however, with the blink, some solution may fall onto the ocular surface. The objective of this study was to assess the effects of LATISSE on the ocular surface over two months. Methods: Non-dry eye participants interested in eyelash lengthening were invited to a prospective uncontrolled, open-label clinical study using LATISSE for two months. Eyelash length, subjective symptoms, tear film stability, osmolarity, ocular redness and intraocular pressure were evaluated at baseline (T0) and at one (T1) and two months (T2). Results: Twenty-eight women (ages 18 to 29) entered the study. Fifteen completed the study with five who discontinued due to burning upon instillation and eight were lost to follow-up. Average eyelash length increased at each time (p < 0.001). Dryness, burning and grittiness remained low (less than 25/100) throughout the trial with dryness showing a significant change between T0 and T1 (p = 0.04), but not between T1 and T2 (p > 0.05). No difference (p > 0.05) was noted for the non-invasive break-up time, photochromametry or tear osmolarity. Intraocular pressure showed a decrease with time but translated to only a one to two mmHg change, which was not clinically relevant. Conclusions: LATISSE increases eyelash length within a short time (less than two months). Patients seeking eyelash enhancement options should be educated as to the use, precautions and any secondary effects, including the potential for discomfort upon instillation.
Eyelashes (or cilia) along with the eyelids play an important role in protecting the ocular surface from debris, dust and other small exogenous particles. 1, 2 Other than the protective aspect of eyelashes, longer thicker eyelashes are also considered a desirable trait and a sign of beauty in some cultures. 3 The proliferation of products for eyelash enhancement in the marketplace is an attestation to this fascination for cosmesis. The consumer has several options to enhance the look of their eyelashes with mascara, lash extensions, lash dyes or tints and eyelash growth-enhancing products. 4 The global cosmetic market is estimated to be around a $155 billion industry, 5 with the USA 6 leading the way ($62 billion) as the market leader. Mascara sales in the USA alone accounted for $329.5 million in 2014. 6 It goes without saying that the loss of eyelashes can be devastating and can lead to social and self-esteem issues. 7 Loss of eyelashes can be due to a variety of medical conditions, including trichotillomania (impulsive disorder in which a person pulls out their hair, which may include lashes), eyelash hypotrichosis (inadequate amount) and madarosis (loss of eyebrows or eyelashes). Madarosis can arise from dermatological (that is, eczema, dermatitis), systemic (that is, thyroid and autoimmune disorders), nutritional deficiencies, trauma and ocular conditions (blepharitis). 8 Madarosis and hypotrichosis can also be induced by drugs and chemotherapy. 8 Eyelashes after chemotherapy often grow back thinner, less dense and lighter than their original counterparts. 9, 10 Improving the look of eyelashes can enhance the cancer patient's overall cosmesis and sense of self and a visual encouragement that they are on their way to recovery.
In contrast to the attention that the eyelash-enhancing industry has attracted, surprisingly, little is known about the biology of eyelashes. Eyelashes, unlike scalp hair, have a shorter growth cycle, undergo greying much later in life and do not possess arrector pili muscles (lashes cannot 'stand up'). 7 Upper eyelashes tend to be more numerous (90 to 160) and grow longer (eight to 12 mm) than their lower counterparts (density 75 to 80, length six to eight mm). 1, 2, 11 They grow in imperfect rows (five to six upper; three to four lower) to protect the entire cornea from exogenous debris, at a rate of 0.12 to 0.13 mm per day. 1, 7, 11 The eyelash begins to grow at the 12th week of gestation and curves outward so that the upper and lower eyelashes do not intertwine with the blink. 7 Eyelashes are densely supplied with nerves causing them to elicit a blink at the slightest stimulation in an attempt to protect the eye. 2 Ethnic differences exist in eyelash morphology. For example, Asians have a reduced curve/curl to their lashes and are thicker in diameter than lashes of Caucasians. 12 The eyelash growth cycle [12] [13] [14] ( Figure 1 ) begins with the anagen (growth) phase lasting one to two months, followed by a catagen (transition) phase where the elements of the follicle undergo programmed cell death (termed apoptosis) lasting 15 days. The telogen (resting or dormant) phase may last for four to nine months before the eyelash falls out during the exogen phase. The growth cycle of human eyelashes is asynchronous, hence at any one time, individual lashes can be at different phases. The total growth cycle of eyelashes is estimated to be between five to 12 months.
Patients with glaucoma using prostaglandin analogues, such as bimatoprost, travoprost and latanoprost, reported a side effect of having longer fuller lashes with the use of their drops. 4, 14, 15 For some, the length became problematic to the point that lashes would smudge the inner surface of eyeglasses with each blink. 16 Others noticed an interocular difference in eyelash length when on monotherapy with prostaglandin analogues. 17, 18 This unexpected 'positive' side effect of prostaglandin analogues to lengthen eyelashes has been studied extensively in the literature 13, 14, 17, [19] [20] [21] and prompted the creation of a product specific for eyelash lengthening, using a prostamide analogue. [22] [23] [24] [25] Although its precise mode of action is not entirely understood, it is believed that prostamide prolongs the anagen phase and shortens the telogen phase of the eyelash growth cycle, resulting in lengthening of eyelashes. 13, 23 LATISSE (Allergan, Irvine, California, USA), a prostamide analogue, consists of 0.03 per cent bimatoprost topical solution combined with benzalkonium chloride (BAK) as its preservative. BAK, commonly found in cosmetics, eye drops and topical skin medications, is a quaternary ammonium compound effective against Grampositive and negative organisms; 26 however, it has also been reported as being irritating to the ocular surface and, in some cases, may lead to hypersensitivity. [26] [27] [28] [29] The association of BAK and the effects on the ocular surface have been well documented in the literature, so much so that more recently glaucoma medications are being formulated with no preservatives or with preservative systems that do not include BAK.
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Although LATISSE is not instilled in the eye, like glaucoma medication, the BAK contained in the product comes in direct contact with the lid margin and can, in theory, spill over onto the ocular surface with the action of a blink and cause ocular redness or discomfort. Hence, the objective of this study was to assess the effects of LATISSE specifically on the ocular surface. The prospective uncontrolled, openlabel clinical study required participants to be present for a total of three experimental sessions at one-month intervals. At each visit, several assessments were performed, including subjective symptoms, tear film stability, tear osmolarity, ocular redness and measurement of intraocular pressure (IOP).
METHODS
Subjective symptoms were assessed using the OSDI 35 and a five-symptom subjective scale. The OSDI is a well-established, validated questionnaire consisting of 12 questions, which addresses symptoms related to dry eyes and is scored on a scale from zero to 100 with higher numbers indicating higher degrees of dry eye severity. Additionally, five symptoms common to dry eye patients (comfort, burning, dryness, grittiness and clarity of vision) were selfreported on a continuous scale from zero to 100.
Tear film stability was evaluated using a corneal topographer (Atlas Corneal Topographer, Zeiss, Germany), which uses concentric mires to be reflected off the corneal surface. The time, measured in seconds, to observe a distortion of the reflected mires on the cornea was noted as the non-invasive break-up time (NIBUT).
The tear osmolarity was measured using the TearLab osmometer (TearLab, San Diego, California, USA). Values greater than 308 mOsm/litre are indicative of a hyperosmolar tear film and dry eye disease. 37 Ocular redness is typically evaluated subjectively using grading scales in clinical practice. 36, [38] [39] [40] The literature has demonstrated that objective methods are more precise than subjective ones for evaluating conjunctival redness and may be better suited for research, to limit inter-observer variability. [41] [42] [43] In an attempt to define conjunctival redness more objectively, a new method previously described 44, 45 to measure blood oxygenation in small retinal blood vessels, was adapted for this protocol, using a photochromameter, which measures luminance reflectivity from the tissue being evaluated as well as the chromaticity of the reflected light in x, y co-ordinates using the CIE 1931 chromaticity diagram. 46 The redness could be quantified by its chromaticity, x and y co-ordinates, each with a value ranging from zero to one from the colour space on the CIE diagram. The direction of the resulting vector from a reference C light (typical of slitlamp light sources) on the CIE diagram to the measurement point will determine the dominant hue (colour). The vector length represents the saturation of the redness. As the conjunctival surface does not change its pigmentation, especially in the red range, its hue should remain constant; however, an increase in saturation along the same vector is obtained if the eye becomes more 'red'. 44 The ocular surface was assessed at each visit using a biomicroscope for ocular staining and hyperaemia (using the IER clinical grading scale) and subsequently measured using a handheld photochromameter (Konica Model CS-100A, Minolta, Tokyo, Japan) to quantify the ocular redness of the conjunctiva, using uniform light from a slitlamp equivalent to a standard C light source. It is a non-invasive technique, easy to use and only takes a few seconds to measure (Figure 2 ). Three measurements were taken on the bulbar conjunctiva, on either side corresponding to the nasal and temporal conjunctiva. The photochromameter measures both the hue and saturation levels.
The IOP was measured at baseline and at each visit using the Ocular Response Analyzer (Reichert Technologies, New York, New York, USA). A non-invasive method was preferred for IOP measurement to avoid the instillation of yet other components (such as anaesthetics) on the ocular surface. At each visit, the order of testing was; OSDI, subjective symptoms, NIBUT, osmolarity, photochromameter, IOP and photography. Following the baseline measurements (T0), each participant was educated on how to use the test product as per manufacturer's instructions. 23, 24 At each visit, the upper central lashes, 15 mm from the outer canthus, were measured using a millimetric ruler and photographed using a photo-slitlamp (Nikon D100 digital camera mounted on a Topcon SL-D7 biomicroscope) and captured using the IMAGEnet 2000 LITE (version 2.14, Topcon) imaging software.
Statistical analysis comprised parametric (repeated-measures analysis of variance) and non-parametric (Mann-Whitney U-test) evaluation at an alpha level of 0.05 using IBM SPSS 22.0 (IBM, Armonk, New York, USA).
RESULTS
Twenty-eight women between the ages of 18 to 29 years (average 23.82 AE 3.53 standard deviation) participated in the study. Thirteen participants did not complete the study, with five who discontinued due to burning upon instillation with accompanying ocular redness, and eight who were lost to follow-up. Of the 13 participants who did not complete the study, six dropped out after one month (at T1) and seven after two months (at T2). A review of the group that remained versus the group that did not complete the study revealed that there was a small difference in age (mean age of 25 years for the study group versus 22.5 for the group that did not complete the study) but this was not significant (p = 0.56). The groups also did not differ (p > 0.05) in entering OSDI score and entering NIBUT for the right and left eyes.
Average eyelash length increased significantly at each time compared to the previous measure (Figure 3 ) from 6.5 AE 0.26 (standard error of the mean) mm for the right eye (OD) and 6.7 AE 0.29 mm for the ). An example of eyelash lengthening before and after treatment can be appreciated in Figure 4 .
All participants in the study had entered OSDI scores less than 13/100 (indicative of non-dry eye) with no significant change (p > 0.05) over the two-month use of LATISSE. Participants were also asked to rate five symptoms (comfort, clarity of vision, dryness, burning and grittiness) at each visit. Comfort and clarity of vision were self-reported on a scale of zero to 100, with higher numbers indicative of better outcomes. Clarity of vision scores remained high (more than 95 of 100) and unchanged throughout the two months (p > 0.05). A possible statistical trend emerged toward a decrease in comfort scores with time ( Figure 5 ) (p = 0.07).
Dryness, burning and grittiness were also self-reported using a scale of zero to 100, with higher numbers indicative of worsening symptoms. All three remained low (less than 25 of 100) throughout the trial ( Figure 6 ) with dryness showing a significant change between T0 and T1 (p = 0.04) but not between T1 and T2 (p > 0.05).
No difference (p > 0.05) was noted for the NIBUT, ocular staining and photochromametry (both hue and saturation) values over the course of the two months for either eye. Tear osmolarity did not reveal a significant change (p = 0.08) over time; however, a possible trend toward higher values was noted at T2 as compared to T0 (Figure 7) .
IOP showed an effect of time only in the right eye (p = 0.006), revealing a decrease between T0 and T1 (p = 0.02) but not thereafter (p = 0.44). There was a possible trend toward a significant change in the left eye (p = 0.052) (Figure 8) . The results of all the ocular parameters evaluated are summarised in Table 1 .
DISCUSSION
The goal of the present study was to evaluate the effects of LATISSE on the ocular surface. Tear film stability, ocular redness and tear film osmolarity, overall comfort, clarity of vision and OSDI scores were not affected over a two-month trial with the test product. Self-reported symptoms (dryness, grittiness and burning) remained low with 'dryness' increasing only within the first month of use. Similarly, IOP decreased slightly within the first month but was not clinically significant.
During this two-month study, participant eyelashes grew approximately 50 per cent longer with the use of the test product (Figure 3) , further supporting the effectiveness of prostamide on lash growth. 13, 19 The Food and Drug Administration clinical trial of LATISSE, on 278 adult patients, revealed an improvement of lash growth at eight, 12 and 16 weeks of a four-month trial. 23 Patients seeking to enhance their eyelashes, be it for aesthetic purposes or for medically induced reasons, can observe a visible lengthening quickly, possibly as early as two months, as in the present study.
Previously reported side effects of LATISSE are mainly ocular and include itching (pruritis) of the eyes (most common at less than four per cent of © 2017 Optometry Australia participants), conjunctival hyperaemia, ocular irritation, dry eye symptoms, redness (erythema) of the eyelid and lid hyperpigmentation. 23 In the present study, five participants discontinued due to burning upon application of LATISSE, which represents 17.8 per cent of participants. Although 'burning' was not among the reported side effects of clinical trials, 23 ocular discomfort can be described in numerous ways by people, including dryness, irritation, burning, stinging et cetera. Nonetheless, this remains a higher rate of side effects than the previously reported four per cent, but may be specific to the population studied. Eight others were lost to follow up and their reasons for discontinuation could not be addressed. Out of the remaining 15 participants, no side effects were reported, such as lid hyperpigmentation, erythema or itching.
Patients should be properly educated as to the application of LATISSE, including removing makeup and contact lenses prior to use and applying the product using one disposable applicator for each upper eyelid margin on a nightly basis. 23 Some product highlights and recommendations are summarised in Table 2 . Patients should also be made aware of potential side effects related to LATISSE, of which itching is the most commonly reported. 23 Lid hyperpigmentation or darkening of the skin around the eyes, can also occur with the use of prostamide; however, this is typically reversible with discontinuation of the product. 23, 47 Patients who do not comply with the recommended application protocol or who are not dextrous enough, may encounter more side effects, so patient education prior to use is key.
Anti-glaucoma drugs containing BAK displayed adverse reactions such as dry eye, stinging and burning sensations. 30, 34 Participants in the present study reported significant discomfort and dryness with use of the test product, five of whom discontinued the study due to discomfort from a burning sensation. Based on the presented results, it may be particularly valuable to inform novice users that symptoms of dryness and discomfort are possible and may occur early within the first month of treatment ( Figures 5 and 6 ), helping to alleviate any concerns in the early use of the product.
LATISSE had no effect (p > 0.05) on tear film stability (as measured by the NIBUT), tear film osmolarity or ocular redness during the two-month use. Although the test product is applied to the eyelid margin and not directly in the eye, it is entirely plausible that with the blink, some ingredients may spill over onto the ocular surface and have the potential to affect it. BAK, the preservative in LATISSE, known to be irritating to the ocular surface 26, 27, 29, 48 and affect tear film stability 31 may, in part, contribute to ocular irritation, discomfort and symptoms of dryness, potentially altering tear film osmolarity. Tear osmolarity in the present study did not reveal a significant change (p = 0.08) over time; however, a trend toward higher values was noted at two months ( Figure 7 ). The osmolality of LATISSE is around 290 mOsmol/kg, 23 close to that of normal tears. 49 The trend toward hyperosmolarity may be more of an indirect effect of the BAK spilling onto the ocular surface. Given that LATISSE is a product to be used longterm, increased exposure and contact time of any ingredient on the ocular surface may have an effect on it; however, at this time, to pinpoint that BAK is the culprit is premature at best and requires further study. Contact lens wearers should be reminded to remove their contact lenses prior to applying LATISSE and waiting at least 15 minutes before insertion of their lenses, as BAK can be absorbed by soft contact lenses and prolong contact time with the ocular surface. 23, 26, 29 Bimatoprost 0.03 per cent produces conjunctival hyperaemia, when used as an ophthalmic therapy in glaucoma patients. 50 Although conjunctival redness is a potential side effect of the test product, photochromatometry used in the present study, an objective measurement of conjunctival redness did not show a significant change in terms of hue or saturation during the two-month use. Possible Table 1 . Ocular measurements at baseline and over two months of using LATISSE Effects of LATISSE on the eye Bitton, Courey, Giancola, Diaconu, Wise and Wittich explanations include: only a small quantity of LATISSE reaches the ocular surface with blinking and is not enough to significantly cause conjunctival hyperaemia; two months may not be long enough to show an effect; the product has no effect on conjunctival hyperaemia. An objective assessment of bulbar redness is preferred over subjective evaluation and has shown to be more precise at detecting smaller changes. 41 As the major pigment in the conjunctiva comes from the chromophores found in the red blood cells, the hue is unlikely to change within a twomonth study. Hence, the saturation is the main measurement of interest to evaluate if the bulbar conjunctival redness changes and, in this study, it did not. That being said, care is needed in the order of testing with a photochromameter, as the use of fluorescein on the ocular surface can affect the chromaticity measurements.
The clinical trial using LATISSE revealed a decrease in IOP; however, the magnitude of the reduction was not deemed clinically relevant. 23 The present study found similar results, as there was a possible reduction in IOP from baseline in one eye and a trend in the other. It represented only a one to two mmHg change, which may not be clinically relevant, as there exists a diurnal variation in IOP of approximately five mmHg in normal adults. [51] [52] [53] The present study ended at two months and hence, we do not know if the reduction in IOP was limited to the initial use of the product or would progress with use. Consequently, our recommendation is to measure IOP prior to use and at periodic intervals, in nonglaucoma patients using eyelash enhancement products with prostamide. It goes without saying that improper use of LATISSE, such as increased dosage or application to the inner surface of the lid margin (as opposed to the outer dermal side) may result in more product spilling onto the eye and increased contact time with the ocular surface, potentially increasing adverse effects.
It is noteworthy to mention that if a patient is being monitored for the effectiveness of a prostaglandin analogue medication, concomitant use of LATISSE may have a reduction in the IOP lowering effect. 23 Hence, it may be prudent to counsel glaucoma patients on prostaglandin analogues and the use of eyelashenhancing products that contain prostamide and closely monitor their IOP.
Overall LATISSE is well tolerated by participants who completed the protocol and may be an effective eyelash enhancement option for patients with hypotrichosis. Other eyelash enhancement options are not without risks, such as mascara, which needs to be replaced periodically as the dark moist environment is a breeding ground for microorganisms and prolonged use can contribute to lash loss and structural damage to the cuticle of the lash. [54] [55] [56] Similarly, eyelash extensions can be a health risk due to the potential for allergic reactions from the glue and the risk of infection from the microorganisms that the extensions themselves may harbour. 57 
CONCLUSION
LATISSE increases eyelash length within a short time (less than two months). Patients interested in LATISSE should be educated as to the use, precautions and any secondary effects, such as the potential for discomfort upon instillation. This side effect may be due to the BAK preservative; however, further studies are needed to corroborate this.
Dependent on the local therapeutic regulations, optometrists may not have the right to prescribe LATISSE. Regardless, it is important to know and discuss effects on the ocular surface with patients seeking eyelash enhancement options and to monitor IOP, with particular attention for glaucoma patients using prostaglandin analogues.
LATISSE

Indication
To treat hypotrichosis of the eyelashes
Product information
Active ingredient: Bimatoprost 0.03 per cent sterile solution (a prostamide analogue)
Non-medicinal ingredient: benkalkonium chloride 0.05 mg/ml (preservative), sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate and purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust the pH 
